WebMar 21, 2024 · Therapeutic standard options include conventional treatments (surgery, radiotherapy, chemotherapy) and, more recently, immunotherapy (6–8). Thus, since 2003 the first-line standard-of-care for unresectable MPM has been chemotherapy based on the combination of a DNA cross-linking agent (cisplatin or carboplatin) and an antifolate … WebNov 23, 2024 · Recently, immunotherapy has demonstrated clinical activity in extensive-stage SCLC (ES-SCLC). The CASPIAN trial assessed durvalumab, with or without tremelimumab, in combination with etoposide plus either cisplatin or carboplatin (platinum-etoposide) in treatment-naive patients with ES-SCLC. Methods:
Expanded Role for Immunotherapy to Treat Endometrial Cancer
WebHead and neck squamous cell carcinoma (HNSCC) has been treated for decades with cisplatin chemotherapy, and anti-PD-1 immunotherapy has recently been approved for … WebSep 20, 2024 · Cisplatin / pharmacology Dendritic Cells / drug effects Galectin 3 / drug effects Humans Interleukin-10 / metabolism Interleukin-6 / metabolism Lung Neoplasms / drug therapy* Lung Neoplasms / immunology Macrophage-1 Antigen / drug effects Macrophages / drug effects* Mice Polysaccharides / pharmacology* Quality of Life T … philipcooper3 bigpond.com e mail
Eligibility for and Response to Checkpoint Inhibitor …
WebMay 26, 2024 · Key exclusion criteria included radiotherapy (except palliative), endocrine therapy, immunotherapy or chemotherapy within the 4 weeks prior to receiving study therapy, more than six cycles of... WebMay 3, 2024 · HNSCC indicates head and neck squamous cell carcinoma; MSI-H, microsatellite instability–high; and PD-L1, programmed cell death ligand 1. Table. Eligibility and Benefit for All Cancers and Benefit for … WebApr 12, 2024 · The combination of the chemotherapy drugs cisplatin and paclitaxel has long been the standard treatment for women with advanced or recurrent endometrial cancer. But treatment options for these two groups of patients have changed recently, largely because of advances in immunotherapy. philip conwisar md sherman oaks